Try it
Microbiology · Virology: ganciclovir-resistant cytomegalovirus
Sample itemA kidney transplant recipient has cytomegalovirus viraemia that rises despite 3 weeks of adequately dosed intravenous ganciclovir. Genotyping shows a mutation in the UL97 gene. What is the most appropriate change in therapy?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
D. Intravenous foscarnet
Ganciclovir must be monophosphorylated by the viral UL97 kinase before host kinases complete activation, and UL97 mutations are the commonest cause of resistance. Foscarnet binds the pyrophosphate site of the DNA polymerase directly and needs no viral kinase activation, so it remains active. Its main toxicity is nephrotoxicity and electrolyte disturbance.
Option by option
A. Continue the same ganciclovir for a longer course
Longer ganciclovir cannot overcome a phosphorylation defect.
B. High-dose oral aciclovir
Aciclovir needs a thymidine kinase that cytomegalovirus lacks, so it is a poor option.
C. Oral valganciclovir at the same dose
Valganciclovir is a prodrug of ganciclovir and shares the same activation step.
D. Intravenous foscarnet (correct)
Foscarnet acts directly on viral DNA polymerase and bypasses the defective kinase step.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Microbiology questions
- BacteriologyA patient has profuse painless watery 'rice-water' stools and rapid dehydration. The cau…
- Culture mediaThayer–Martin medium is used selectively to isolate which organism?
- Immunology and serologyWhich of the following is a non-treponemal test for syphilis?
- BacteriologyAlbert's stain is used to demonstrate which of the following?